Cargando…

Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report

We report a rare case of PDL1-negative advanced gastric adenocarcinoma that improved significantly after camrelizumab plus chemotherapy followed by camrelizumab plus capecitabine as first-line therapy. A 65-year-old woman was diagnosed with a gastric adenocarcinoma in 2017 via contrast-enhanced comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jieheng, Yang, Jianying, Wang, Wenping, Lin, Xiaotong, Cao, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727688/
https://www.ncbi.nlm.nih.gov/pubmed/35004297
http://dx.doi.org/10.3389/fonc.2021.775147
_version_ 1784626571818041344
author Lin, Jieheng
Yang, Jianying
Wang, Wenping
Lin, Xiaotong
Cao, Yang
author_facet Lin, Jieheng
Yang, Jianying
Wang, Wenping
Lin, Xiaotong
Cao, Yang
author_sort Lin, Jieheng
collection PubMed
description We report a rare case of PDL1-negative advanced gastric adenocarcinoma that improved significantly after camrelizumab plus chemotherapy followed by camrelizumab plus capecitabine as first-line therapy. A 65-year-old woman was diagnosed with a gastric adenocarcinoma in 2017 via contrast-enhanced computed tomography (CT) and endoscopic biopsy. She stabilised after preoperative neoadjuvant chemotherapy, surgery, and postoperative adjuvant chemotherapy. In September 2019, positron emission tomography (PET)/CT re-examination suggested a peritoneal metastasis and multiple lymph node metastases. She then received six cycles of camrelizumab plus chemotherapy. PET/CT indicated that the metastatic foci had disappeared and that she had achieved a clinical complete response(CCR). She was followed-up with camrelizumab plus capecitabine (maintenance therapy). At the time of writing, her progression-free survival is more than 14 months and her quality of life is good. Thus, camrelizumab plus chemotherapy is a useful first-line treatment for HER2- and PD-L1-negative advanced gastric adenocarcinoma.
format Online
Article
Text
id pubmed-8727688
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87276882022-01-06 Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report Lin, Jieheng Yang, Jianying Wang, Wenping Lin, Xiaotong Cao, Yang Front Oncol Oncology We report a rare case of PDL1-negative advanced gastric adenocarcinoma that improved significantly after camrelizumab plus chemotherapy followed by camrelizumab plus capecitabine as first-line therapy. A 65-year-old woman was diagnosed with a gastric adenocarcinoma in 2017 via contrast-enhanced computed tomography (CT) and endoscopic biopsy. She stabilised after preoperative neoadjuvant chemotherapy, surgery, and postoperative adjuvant chemotherapy. In September 2019, positron emission tomography (PET)/CT re-examination suggested a peritoneal metastasis and multiple lymph node metastases. She then received six cycles of camrelizumab plus chemotherapy. PET/CT indicated that the metastatic foci had disappeared and that she had achieved a clinical complete response(CCR). She was followed-up with camrelizumab plus capecitabine (maintenance therapy). At the time of writing, her progression-free survival is more than 14 months and her quality of life is good. Thus, camrelizumab plus chemotherapy is a useful first-line treatment for HER2- and PD-L1-negative advanced gastric adenocarcinoma. Frontiers Media S.A. 2021-12-22 /pmc/articles/PMC8727688/ /pubmed/35004297 http://dx.doi.org/10.3389/fonc.2021.775147 Text en Copyright © 2021 Lin, Yang, Wang, Lin and Cao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Lin, Jieheng
Yang, Jianying
Wang, Wenping
Lin, Xiaotong
Cao, Yang
Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report
title Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report
title_full Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report
title_fullStr Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report
title_full_unstemmed Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report
title_short Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report
title_sort clinical complete remission of an advanced gastric adenocarcinoma after camrelizumab plus chemotherapy followed by camrelizumab plus capecitabine: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727688/
https://www.ncbi.nlm.nih.gov/pubmed/35004297
http://dx.doi.org/10.3389/fonc.2021.775147
work_keys_str_mv AT linjieheng clinicalcompleteremissionofanadvancedgastricadenocarcinomaaftercamrelizumabpluschemotherapyfollowedbycamrelizumabpluscapecitabineacasereport
AT yangjianying clinicalcompleteremissionofanadvancedgastricadenocarcinomaaftercamrelizumabpluschemotherapyfollowedbycamrelizumabpluscapecitabineacasereport
AT wangwenping clinicalcompleteremissionofanadvancedgastricadenocarcinomaaftercamrelizumabpluschemotherapyfollowedbycamrelizumabpluscapecitabineacasereport
AT linxiaotong clinicalcompleteremissionofanadvancedgastricadenocarcinomaaftercamrelizumabpluschemotherapyfollowedbycamrelizumabpluscapecitabineacasereport
AT caoyang clinicalcompleteremissionofanadvancedgastricadenocarcinomaaftercamrelizumabpluschemotherapyfollowedbycamrelizumabpluscapecitabineacasereport